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Generation of a therapeutic immune response against a
diverse set of antigens expressed by a patient’s cancer is
a central goal of cancer immunotherapy. This goal is
important because diverse responses may prevent escape
of antigen loss variants. To accomplish this goal we
have developed tumor-derived autophagosome-enriched
vaccines, “DRibbles”, that sequester a complex mixture
of proteins including cancer antigens and damage-asso-
ciated molecular pattern molecules (DAMPs). In precli-
nical studies, combination immunotherapy with this
vaccine approach provides significant protection from
tumor challenge and therapeutic efficacy against estab-
lished tumors. DRibble vaccines are superior to whole
tumor vaccines in both protection and therapy studies,
and demonstrated efficacy even when used across a
complete MHC mismatch, opening the way for a clinical
off-the-shelf cancer vaccine. UbiVac has produced an
allogeneic DRibble vaccine (DPV-001) from two human
NSCLC cell lines - UbiLT3 (non-specific histopathology)
and UbiLT6 (adenocarcinoma-like) - that is currently
used in a phase II trial for definitively treated stage
IIIA/B NSCLC. Microarray analysis was performed on
the cells at time of vaccine production and the vaccine
was characterized by western blot, flow cytometry and
liquid chromatography tandem mass spectrometry. Over
25 cancer-associated proteins have been identified in the
DPV-001 vaccine including nine from the NCI’s list
of prioritized cancer antigens. Additionally found in
this vaccine are multiple DAMPs, including S100A8,
nucleolin, calreticulin, HMGB1, HSP70, HSP90, DNAs
and RNAs. UbiLT3 DRibbles - but not whole cell irra-
diated vaccine - potently stimulates TLR 2, 3, 4, 7, and 9.
Since many previously identified cancer antigens are cre-
ated by genomic mutations and rearrangements, we per-
formed exome sequencing of UbiLT3 and UbiLT6 and are
searching for epitopes which could help break tolerance
and improve vaccine efficacy. Together these data docu-
ment that the DPV-001 vaccine contains antigens relevant
for immunotherapy of cancer. In addition to NSCLC, we,
and our collaborators, are exploring the application of this
vaccine for the immunotherapy of colon, prostate and
HNSCC.
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